CN Patent

CN121729228A — 在治疗心力衰竭中使用的化合物azd5462

Assigned to AstraZeneca AB · Expires 2026-03-24 · 0y expired

What this patent protects

本公开涉及用于治疗心力衰竭的给药方案、方法和药物组合物，该给药方案、方法和药物组合物包含施用化合物（I）或其药学上可接受的盐。

USPTO Abstract

本公开涉及用于治疗心力衰竭的给药方案、方法和药物组合物，该给药方案、方法和药物组合物包含施用化合物（I）或其药学上可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN121729228A
Jurisdiction
CN
Classification
—
Expires
2026-03-24
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.